Satellos Bioscience Inc Stock Price, News & Analysis

Satellos Bioscience (OTCQB: MSCLF, TSX: MSCL) will participate in two investor conferences in New York in December 2025: Piper Sandler 37th Annual Healthcare Conference on Dec 3, 2025 at 12:50 p.m. ET (presentation, live webcast with replay) and Oppenheimer Movers in Rare Disease Summit on Dec 11, 2025 at 1:10 p.m. ET (panel on polypharmacy in DMD and neuromuscular disease).

The Satellos leadership team will also hold one-on-one investor meetings during the events; meeting requests can be made through Piper Sandler/Oppenheimer representatives or by emailing ir@satellos.com.

Satellos (OTCQB: MSCLF) announced a Nature Communications publication (Nov 18, 2025) reporting that Duchenne muscular dystrophy begins during fetal development as a muscle stem cell disease with loss of polarity and reduced myogenic progenitors.

Researchers showed that blocking the protein AAK1 restored stem cell polarity, progenitor production, and normal muscle formation in dystrophic models, supporting AAK1 inhibition and Satellos' candidate SAT-3247 as a regenerative approach.

Satellos (TSX: MSCL, OTCQB: MSCLF) reported Q3 2025 results and corporate updates on November 14, 2025. Key developments include the appointment of Mark Nawacki to the board, completion of an IND submission to the U.S. FDA and parallel global regulatory filings to support a Phase 2 pediatric trial of SAT-3247, and dosing the first patient in the long-term adult follow-up study LT-001.

Clinical data presented showed mean improvements in grip strength (dominant hand +118.6%, non-dominant +97.9%) and respiratory function (predicted FVC +5.8%) in Phase 1b participants. Financially, cash and short-term investments were $34.6M USD ($48.2M total) at Sept 30, 2025; Q3 net loss was $5.8M ($0.03/share). The company expects to enroll the first pediatric Phase 2 patient by end of 2025 and to report additional adult data in Q1 2026.

Satellos (OTCQB: MSCLF) announced that its leadership will participate in two investor conferences in November 2025: a fireside chat and 1x1 meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference on Nov 10, 2025 at 3:00 PM ET in Boston, and a presentation plus 1x1 meetings at the Stifel Healthcare Conference on Nov 12, 2025 at 2:40 PM ET in New York.

The fireside chat and presentation will be available via live webcast on the company’s Events and Presentations page, with a replay available after the presentations.

Satellos (OTCQB: MSCLF) announced the first adult patient has been dosed in LT-001, an open-label long-term follow-up study of SAT-3247 in adult males with Duchenne muscular dystrophy.

The 11-month study will evaluate safety, MRI muscle composition, functional outcomes, and serum biomarkers in participants who completed Part D of the Phase 1b study. Results after the initial 3 months are anticipated in early 2026, then reported quarterly. The trial is underway at St Vincent’s Hospital, Melbourne, with plans to enroll up to 10 new participants in Australia and to open sites in the U.S., subject to regulatory and site approvals.

Satellos (OTCQB:MSCLF) reported new Phase 1a/b data showing SAT-3247 was safe and well tolerated and produced early functional gains in five adults with Duchenne muscular dystrophy after 28 days.

Key results: maximum grip strength increased mean 118.6% (dominant hand) and 97.9% (non-dominant hand), rising from ~2 kg to ~4 kg; predicted forced vital capacity improved mean 5.8%. No drug-related adverse events of moderate severity or higher and no dose-limiting toxicities were observed. Higher drug concentrations on Day 15 and higher baseline creatinine correlated with greater grip gains.

The five adult participants are invited to an 11-month open-label follow-up, and the company plans a Phase 2 randomized, double-blind, placebo-controlled study in ambulatory children with DMD with regulatory filings submitted.

Satellos Bioscience (OTCQB: MSCLF) announced it will present two scientific posters at the 30th Annual Congress of the World Muscle Society (WMS) in Vienna, Austria, from October 7-11, 2025. The presentations will feature new analyses from the Phase 1b study of SAT-3247, their investigational treatment for Duchenne muscular dystrophy.

The company's Chief Medical Officer, Dr. Wildon Farwell, will present late-breaking data from the Phase 1a/b study in healthy volunteers and adult Duchenne patients. Additionally, Dr. Ryan Mitchell, SVP of Medical & Scientific Affairs, will provide a clinical progress update on SAT-3247, which is designed to address deficits in muscle repair and regeneration.

Satellos Bioscience (OTCQB: MSCLF) has submitted an Investigational New Drug (IND) application to the FDA and parallel regulatory filings globally to initiate a Phase 2 clinical trial of SAT-3247 in children with Duchenne muscular dystrophy (DMD).

The three-month randomized, placebo-controlled study will evaluate safety, pharmacokinetics, and functional measures in ambulatory children, with the first patient enrollment expected by end of 2025. The company's Phase 1b study showed promising results, with patients experiencing doubled grip strength and 5% improvement in lung function.

Additionally, Satellos has initiated an 11-month extension study in Australia and received C$1.04 million through warrant exercises in Q3 2025.

Satellos Bioscience (OTCQB:MSCLF), a clinical-stage biotech company focused on developing treatments for degenerative muscle diseases, has announced its participation in four major healthcare investor conferences this September.

The company will attend the Wells Fargo Healthcare Conference (Sept. 3, Boston), Cantor Fitzgerald Global Healthcare Conference (Sept. 5, New York), H.C. Wainwright Global Investment Conference (Sept. 9, New York), and Morgan Stanley Global Healthcare Conference (Sept. 10, New York). Two of these events will feature fireside chats that will be available via webcast on the company's investor relations website.